For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Diadexus, Inc.

USPTO Granted Patents = 47

% Expired Patents = 76.6

CIPO Patents = 2

EPO Patents = 5

Trademarks = 2

Forward Citations = 609

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Yongming Sun (23 out of 23 patents)

Herve Recipon (19 out of 19 patents)

Roberto A Macina (15 out of 15 patents)

4. Susana Salceda (14 out of 14 patents)

5. Robert Cafferkey (14 out of 14 patents)

6. Jackie Papkoff (8 out of 11 patents)

7. Laura Corral (7 out of 8 patents)

8. Iris Simon (6 out of 7 patents)

9. Glenn Ronald Pilkington (6 out of 8 patents)

10. Shujath Ali (6 out of 6 patents)

11. Chenghua Liu (5 out of 17 patents)

12. Gilbert-Andre Keller (4 out of 6 patents)

13. Wenlu Li (4 out of 4 patents)

14. Gundo Diedrich (3 out of 8 patents)

15. Shu-Hui Liu (3 out of 16 patents)

Core Competencies:

Lipoprotein-Associated Phospholipase A2

OVR110 Antibody

Prostate Cancer

Breast Cancer

Gastrointestinal Cancer

Ovarian Specific Genes

Colorectal Cancer

Gynecologic Cancers

Cancer Risk Assessment

Splice Variants

Imaging Methods

Monitoring Methods

47 patents: Sort by Forward Citations

1. 9000132 - Lipoprotein-associated phospholipase A2 antibody compositions and methods of use (2015-04-07),

2. 8906369 - Ovr110 antibody compositions and methods of use (2014-12-09),

3. 8460880 - Compositions, splice variants and methods relating to ovarian specific genes and proteins (2013-06-11),

4. 8444971 - OVR110 antibody compositions and methods of use (2013-05-21),

5. 8354508 - PRO115 antibody compositions and methods of use (2013-01-15),

6. 8287867 - Ovr115 antibody compositions and methods of use (2012-10-16),

7. 8207311 - Ovr115 antibody compositions and methods of use (2012-06-26),

8. 8173434 - PCan065 antibody compositions and methods of use (2012-05-08),

9. 8148093 - Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk (2012-04-03),

10. 8080650 - Pro104 antibody compositions and methods of use (2011-12-20),

11. 8029787 - Method of diagnosing, monitoring, staging, imaging and treating various cancers (2011-10-04),

12. 7964195 - Ovr110 antibody compositions and methods of use (2011-06-21),

13. 7858325 - Method of diagnosing, monitoring, staging, imaging and treating prostate cancer (2010-12-28),

14. 7737255 - Method of diagnosing, monitoring, staging, imaging and treating various cancers (2010-06-15),

15. 7678889 - Compositions and methods relating to ovarian specific genes and proteins (2010-03-16),

Diadexus, Inc. is a biotechnology company based in South San Francisco, California, specializing in the development of innovative diagnostic solutions. The company focuses on lipoprotein-associated phospholipase A2 and its implications in various cancers, including prostate, breast, colorectal, and lung cancers. Diadexus is dedicated to advancing cancer risk assessment through its research on ovarian-specific genes and antibody compositions, aiming to enhance patient outcomes and provide critical insights into cancer biology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

47 Patents

#35 in South San Francisco, CA

#1,752 in California

#7,425 in US

#14,796 in the World

South San Francisco, CA, United States of America

Diadexus, Inc.

Forward Citations = 609

44 inventors:

Yongming Sun (23 out of 23 patents)

Herve Recipon (19 out of 19 patents)

Roberto A Macina (15 out of 15 patents)

4. Susana Salceda (14 out of 14 patents)

5. Robert Cafferkey (14 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…